{
    "id": "52839613",
    "text": "Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases. The company was founded in 1998. Novimmune has six publicly disclosed drug in their pipeline: * NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014 and phase II trials are expected to begin in early 2017. * NI-0401, an anti-CD3\u03b5 antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively. * NI-0501, an anti-IFN\u03b3 antibody, is in development for hemophagocytic lymphohistiocytosis. A phase II/III trial began in 2013 and is ongoing. The FDA awarded breakthrough status to the drug in 2016. * NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases. * NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers. * NI-1801, an anti-CD47, anti- mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors. No drugs have been approved as of yet. == References == Category:Pharmaceutical companies of Switzerland ",
    "title": "Novimmune"
}